Why the study?
Does acetazolamide prevent haemodynamic changes in subjects exposed to acute high altitude hypoxia?
Population
42 subjects (21 males, age 36.8 ± 8.9 years) exposed to acute high altitude hypoxia
Comparison
Acetazolamide 250 mg b.i.d. vs Matching placebo
Design
RCT, randomized, double blind
Follow-up
3 days of exposure to high altitude
Key result
Acetazolamide significantly lowered diastolic (P<0.005), mean (P<0.05), and systolic blood pressure (P<0.05) compared to placebo during acute high altitude exposure.
Authors
Loading...
Acetazolamide may blunt acute high-altitude blood pressure rises in exposed individuals; confirms hemodynamic benefit in this RCT.
RCT (n=42)
Double-blind
randomized
Does acetazolamide prevent haemodynamic changes in subjects exposed to acute high altitude hypoxia?
Acetazolamide blunts the rise in blood pressure and changes in pulse waveform-derived parameters induced by acute high altitude exposure.
p-value: p=<0.005
Parati et al. (2012) conducted an RCT in Acute high altitude exposure (n=42). Acetazolamide vs. Placebo was evaluated on Diastolic and mean blood pressure at high altitude (p=<0.005). Acetazolamide significantly lowered diastolic (P<0.005), mean (P<0.05), and systolic blood pressure (P<0.05) compared to placebo during acute high altitude exposure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: